-

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place on May 13-17, 2025, in New Orleans, Louisiana.

Details for the poster presentation are as follows:

ASGCT 28th Annual Meeting
Poster Title: Toward Treatment with Gene-Modified B Cells Engineered In Vivo Using iGPS Particles
Category: Cell Therapy: H2 – In-Vivo Editing of HSPCs and Immune Cells
Presenter: Russell McConnell, Ph.D., Director, Discovery Research at Kelonia
Date and Time: Wednesday, May 14, 5:30 – 7:00 p.m. CDT

About Kelonia Therapeutics

Kelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Initially focused on developing transformational in vivo CAR-T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at https://www.keloniatx.com/ and follow us on LinkedIn and X.

Contacts

Katherine Smith, Inizio Evoke Comms
katherine.smith@inizioevoke.com

Industry:

Kelonia Therapeutics, Inc.

Release Versions
English

Contacts

Katherine Smith, Inizio Evoke Comms
katherine.smith@inizioevoke.com

More News From Kelonia Therapeutics, Inc.

Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, will be presented in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando,...

Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, today announced that the first patient has been dosed in the inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells, in patients with relapsed and refractory multiple myeloma. “KLN-1010 offers hope to multiple myeloma patients who can’t access today’s CAR-T cell therapies,” said Kevin Friedman, Ph.D., Chief Executi...

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific conferences – the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, taking place on May 7-11, 2024, in Baltimore, Maryland, and the Protein Engineering Summit (PEGS) Boston Summit 2024, taking place on M...
Back to Newsroom